The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

Mumbai: The state health department is ramping up efforts to promote e-RaktKosh — the central govt portal launched in 2016, ...

Measles is unlike other childhood viruses. In severe cases, it can cause pneumonia. About 1 in 1,000 patients develops ...

The first clinical trial under the Cooperative Research and Development Agreement with the National Cancer Institute and ...

Otunba Okubena and I met in Nigeria’s Alternative Medicines market in 1994 when he was about to push into the market his ...

An international group of researchers has identified an important mechanism that enables stem cells to evade immune rejection ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

In a story of collaboration and community, researchers identified intergenerational epigenetic changes caused by war and ...